Praluzatamab ravtansine
As of the edition of 20 October 2026, Praluzatamab ravtansine is an antibody drug conjugate: stopped in 2020; acts on ALCAM.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Stopped, 2020
- Kind
- Antibody drug conjugate
- Registered trials
- 2, 1 stopped early
- Disease areas
- Cancer; Skin and connective tissue; Hormones; Lungs and airways; Pregnancy and women's health; Urinary and reproductive
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Companies that need a new molecule because of this drug
1 company on route A because of this drug.
Companies on route A for this drug
In the product1 company is on route A because of Praluzatamab ravtansine.
See the 1 company on route A for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Target
| Gene | Protein | UniProt |
|---|---|---|
| ALCAM | CD166 antigen | Q13740 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 2 | 2 | 1 | 0 | 1 |
| All trials | 2 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| CytomX Therapeutics | Lead sponsor of trials | 2017 to now |